BofA raised the firm’s price target on BioNTech (BNTX) to $134 from $126 and keeps a Buy rating on the shares. The company’s Q2 results saw revenue well ahead of consensus expectations, with the firm also noting that its COVID revenues provide runway for further pipeline execution, the analyst tells investors in a research note. BioNTech also remains committed to maintaining differentiation through variant-adapted boosters and combo vaccine development, BofA added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- BioNTech SE: Strategic Growth and Innovation in Oncology Amidst Strong Financial Foundation
- Cautious Hold on BioNTech SE Amid Revenue Uncertainty and Competitive Challenges
- BioNTech price target raised to $185 from $181 at Clear Street
- BioNTech SE Reports Strong Financial Results for Mid-2025
- BioNTech Reports Q2 2025 Financials and Strategic Collaborations